JPWO2020191141A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020191141A5 JPWO2020191141A5 JP2021556508A JP2021556508A JPWO2020191141A5 JP WO2020191141 A5 JPWO2020191141 A5 JP WO2020191141A5 JP 2021556508 A JP2021556508 A JP 2021556508A JP 2021556508 A JP2021556508 A JP 2021556508A JP WO2020191141 A5 JPWO2020191141 A5 JP WO2020191141A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- set forth
- srebf1
- nucleotide sequence
- complement
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962820893P | 2019-03-20 | 2019-03-20 | |
| US62/820,893 | 2019-03-20 | ||
| US201962879138P | 2019-07-26 | 2019-07-26 | |
| US62/879,138 | 2019-07-26 | ||
| PCT/US2020/023532 WO2020191141A1 (en) | 2019-03-20 | 2020-03-19 | Treatment of increased lipid levels with sterol regulatory element binding transcription factor 1 (srebf1) inhibitors |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022525545A JP2022525545A (ja) | 2022-05-17 |
| JP2022525545A5 JP2022525545A5 (https=) | 2023-03-22 |
| JPWO2020191141A5 true JPWO2020191141A5 (https=) | 2023-03-22 |
| JP7574206B2 JP7574206B2 (ja) | 2024-10-28 |
Family
ID=70289471
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021556508A Active JP7574206B2 (ja) | 2019-03-20 | 2020-03-19 | ステロール調節エレメント結合転写因子１（ｓｒｅｂｆ１）阻害剤による上昇した脂質レベルの治療 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US11504390B2 (https=) |
| EP (1) | EP3942048A1 (https=) |
| JP (1) | JP7574206B2 (https=) |
| CN (2) | CN116889627A (https=) |
| CA (1) | CA3133000A1 (https=) |
| WO (1) | WO2020191141A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116583291A (zh) * | 2020-12-14 | 2023-08-11 | 雷杰纳荣制药公司 | 用抑制素亚基βE(INHBE)抑制剂治疗代谢病症和心血管疾病的方法 |
| MX2023007012A (es) | 2020-12-14 | 2023-06-27 | Regeneron Pharma | Metodos para tratar los trastornos metabolicos y las enfermedades cardiovasculares con inhibidores de la subunidad beta e de la inhibina (inhbe). |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5688787A (en) | 1991-07-23 | 1997-11-18 | Schering Corporation | Substituted β-lactam compounds useful as hypochlesterolemic agents and processes for the preparation thereof |
| US5631356A (en) | 1992-04-03 | 1997-05-20 | Gist-Brocades, N.V. | Selective N-acylation of amino alcohols |
| LT3595B (en) | 1993-01-21 | 1995-12-27 | Schering Corp | Spirocycloalkyl-substituted azetidinones useful as hypocholesterolemic agents |
| US5631365A (en) | 1993-09-21 | 1997-05-20 | Schering Corporation | Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents |
| FR2710337B1 (fr) | 1993-09-23 | 1995-12-08 | Gerard Coquerel | Procédé de dédoublement de deux antipodes optiques par entraînement polythermique programmé et autoensemencé. |
| US5633246A (en) | 1994-11-18 | 1997-05-27 | Schering Corporation | Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents |
| US5624920A (en) | 1994-11-18 | 1997-04-29 | Schering Corporation | Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents |
| US5656624A (en) | 1994-12-21 | 1997-08-12 | Schering Corporation | 4-[(heterocycloalkyl or heteroaromatic)-substituted phenyl]-2-azetidinones useful as hypolipidemic agents |
| US5756470A (en) | 1996-10-29 | 1998-05-26 | Schering Corporation | Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents |
| US6602710B1 (en) | 1998-08-27 | 2003-08-05 | Chugai Seiyaku Kabushiki Kaisha | Screening method for SREBP pathway-specific inhibitors |
| GB9916757D0 (en) | 1999-07-17 | 1999-09-15 | Glaxo Group Ltd | Method |
| HRP20030498A2 (en) | 2000-12-21 | 2005-04-30 | Aventis Pharma Deutschland Gmbh | Novel 1,2-diphenzylazetidinones, method for producing the same, medicaments containing said compounds, and the use thereof for treating disorders of the lipid metabolism |
| TWI291957B (en) | 2001-02-23 | 2008-01-01 | Kotobuki Pharmaceutical Co Ltd | Beta-lactam compounds, process for repoducing the same and serum cholesterol-lowering agents containing the same |
| US20080249040A1 (en) | 2001-05-18 | 2008-10-09 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of sterol regulatory element binding protein 1 (SREBP1) gene expression using short interfering nucleic acid (siNA) |
| AU2002320621A1 (en) | 2001-07-20 | 2003-03-03 | Incyte Genomics, Inc. | Structural and cytoskeleton-associated proteins |
| WO2003033656A2 (en) * | 2001-10-16 | 2003-04-24 | Exelixis, Inc. | MSREBPs AS MODIFIERS OF THE SREBP PATHWAY AND METHODS OF USE |
| US20050014177A1 (en) | 2003-05-19 | 2005-01-20 | Koustubh Ranade | Human sterol response element binding protein 1 (SREBP1) single nucleotide polymorphisms |
| AU2007275365A1 (en) * | 2006-07-17 | 2008-01-24 | Sirna Therapeutics Inc. | RNA interference mediated inhibition of Proprotein Convertase Subtilisin Kexin 9 (PCSK9) gene expression using short interfering nucleic acid (siNA) |
| AU2007297388A1 (en) | 2006-09-18 | 2008-03-27 | Alnylam Pharmaceuticals, Inc. | RNAi modulation of scap and therapeutic uses thereof |
| JP2010053122A (ja) * | 2008-07-31 | 2010-03-11 | Hayashibara Biochem Lab Inc | 脂質合成阻害剤 |
| US9187746B2 (en) | 2009-09-22 | 2015-11-17 | Alnylam Pharmaceuticals, Inc. | Dual targeting siRNA agents |
| WO2011087857A2 (en) * | 2009-12-22 | 2011-07-21 | The Administrators Of The Tulane Educational Fund | Compositions and methods for treating obesity and diabetes |
| WO2015100257A1 (en) | 2013-12-23 | 2015-07-02 | The General Hospital Corporation | Methods and assays for determining reduced brca1 pathway function in a cancer cell |
| WO2017100542A1 (en) | 2015-12-10 | 2017-06-15 | Alnylam Pharmaceuticals, Inc. | Sterol regulatory element binding protein (srebp) chaperone (scap) irna compositions and methods of use thereof |
| CN105441454B (zh) | 2015-12-23 | 2018-12-11 | 北京大学人民医院 | Scap基因突变体及其应用 |
| MX2018013499A (es) | 2016-05-03 | 2019-09-11 | Lonza Ag | Modulacion del metabolismo lipidico para la produccion de proteinas. |
| WO2019141723A1 (en) * | 2018-01-18 | 2019-07-25 | Roche Innovation Center Copenhagen A/S | Antisense oligonucleotides targeting srebp1 |
| AU2019212959A1 (en) | 2018-01-29 | 2020-09-17 | Capulus Therapeutics, Llc | SREBP inhibitors comprising a 6-membered central ring |
| US11648260B2 (en) | 2018-03-29 | 2023-05-16 | Technion Research And Development Foundation Limitted | Vesicles comprising a PTEN inhibitor and uses of same |
| CN109536610B (zh) * | 2018-12-05 | 2020-10-16 | 西南大学 | Setdb1在调控胆固醇途径中的应用 |
-
2020
- 2020-03-19 JP JP2021556508A patent/JP7574206B2/ja active Active
- 2020-03-19 CN CN202310867404.XA patent/CN116889627A/zh active Pending
- 2020-03-19 EP EP20719278.2A patent/EP3942048A1/en active Pending
- 2020-03-19 US US16/823,634 patent/US11504390B2/en active Active
- 2020-03-19 CN CN202080030927.3A patent/CN113727732B/zh active Active
- 2020-03-19 CA CA3133000A patent/CA3133000A1/en active Pending
- 2020-03-19 WO PCT/US2020/023532 patent/WO2020191141A1/en not_active Ceased
-
2022
- 2022-10-17 US US18/047,026 patent/US20230263821A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2007139811A1 (en) | Methods and kits for linking polymorphic sequences to expanded repeat mutations | |
| JP2006517092A (ja) | 心不全遺伝子の決定及び治療薬スクリーニング | |
| WO2023137265A1 (en) | Triggering receptor expressed on myeloid cells 2 (trem2) variants and uses thereof in treating alzheimer's disease | |
| JP7574206B2 (ja) | ステロール調節エレメント結合転写因子１（ｓｒｅｂｆ１）阻害剤による上昇した脂質レベルの治療 | |
| AU2021335200A9 (en) | Treatment of sepsis with pcsk9 and ldlr modulators | |
| JPWO2020154268A5 (https=) | ||
| JPWO2020191141A5 (https=) | ||
| JP4842256B2 (ja) | 遺伝子一塩基多型解析によるアトピー性皮膚炎の相対罹患危険率の検出方法 | |
| US20220233569A1 (en) | Methods Of Improving Health With Apolipoprotein E (APOE) Inhibitors | |
| JP4242590B2 (ja) | 慢性関節リウマチの疾患感受性遺伝子、及びその利用 | |
| US20080050358A1 (en) | Identification of Snps Associated with Hyperlipidemia, Dyslipidemia and Defective Carbohydrate Metabolism | |
| JPWO2020191163A5 (https=) | ||
| JP2007511474A5 (https=) | ||
| AU2022356375B2 (en) | Reticulocalbin-3 (rcn3) variants and treatment of asthma with interleukin-4 receptor alpha (il4r) antagonists | |
| JPWO2021262601A5 (https=) | ||
| CN117795075A (zh) | 使用溶质载剂家族27成员3(slc27a3)抑制剂治疗哮喘的方法 | |
| CN121175436A (zh) | 用压电式机械敏感离子通道组分1(piezo1)激动剂治疗静脉曲张 | |
| EP4466357A2 (en) | Methods of improving health with apolipoprotein e (apoe) inhibitors | |
| AU2022300980A1 (en) | Treatment of cognitive impairment with alpha-n-acetylgalactosaminide alpha-2,6-sialyltransferase 5 (st6galnac5) inhibitors | |
| EP4409037A1 (en) | Reticulocalbin-3 (rcn3) variants and treatment of asthma with interleukin-4 receptor alpha (il4r) antagonists | |
| AU2022303368A1 (en) | Treatment of hypertension with solute carrier family 9 isoform a3 regulatory factor 2 (slc9a3r2) inhibitors | |
| WO2024059000A1 (en) | Treatment of endometriosis with r-spondin 3 (rspo3) inhibitors | |
| CN118804976A (zh) | 用整联蛋白亚基α1(ITGA1)抑制剂治疗肺部疾患 | |
| JPWO2020139830A5 (https=) | ||
| CN118265529A (zh) | 使用camp应答元件结合蛋白3样3(creb3l3)抑制剂的肝病治疗 |